Cobalis, BESPHarma partner to launch national distribution program for PreHistin Allergy Defense Formula

Aug 6 2010

Cobalis Corp. (Pink Sheets: CLSC) announced today that it has entered into a 5-year distribution partnership agreement with Florida-based BESPHarma, LLC to launch a national distribution program wherein physicians and healthcare providers can offer their patients PreHistin® Allergy Defense Formula directly in their offices. BESPHarma, a specialty healthcare product distribution and marketing company, has a well-developed network of approximately 20,000 physician's offices across the U.S. that have created in-office dispensaries for various medications, providing patients with the convenience of immediate access to their prescription drugs. PreHistin® represents the first non-prescription supplement to be added into the physicians' office dispensary program.

This marks one of the most significant milestones for Cobalis building a fully-integrated marketing and sales program for PreHistin®, by adding the physician, a patient's most trusted health advisor, as an advocate and direct source of PreHistin® for their patients who suffer from seasonal (outdoor) and year-round (indoor) allergies.

BESPHarma Managing Partner Pamela Willis said: "With 1 out of every 5 Americans suffering from allergies, and over 17 million outpatient doctor visits annually to treat allergy symptoms, we see a perfect fit to make PreHistin® immediately available to consumers at the most effective moment in their healthcare: right at the doctor's office. We believe physicians will, in large numbers, quickly adopt providing their allergy patients with a safe, non-drowsy alternative to after-the-symptom antihistamines to help them restore a normal response to allergens. We are excited to partner with Cobalis and represent this unique new approach to allergy care to doctors across the U.S. We are now preparing to introduce PreHistin® to our core network of physicians immediately."

Marty Marion, Cobalis CEO said: "To a consumer suffering from allergies, there is no more important or trusted factor than the advice of their doctor. Making PreHistin® available right at their physician's office is important on several levels. First, it is an opportunity to introduce and build the PreHistin® brand and its benefits to nearly 20,000 physician's offices and their patients. Further, as BESPHarma accelerates placement of PreHistin® throughout their network of physicians' offices, we will see substantial sales of PreHistin® in the very near term. We are very pleased to announce this partnership with BESPHarma and prepare to launch this major sales program immediately."